Alkermes Medicines & Focus: Serious Mental Illness

Alkermes Medicines & Focus: Serious Mental Illness

We are committed to addressing unmet needs in serious mental illness through the development of therapeutic options to support adults living with schizophrenia and bipolar I disorder.

Content from this campaign

"I'm Incredibly Proud to Work at a Company Whose Mission Is To Help Families Like Mine"
Jessica Veri is an Alkermes employee whose personal connection to mental health inspires her to make a meaningful difference in the lives of people living with serious mental illness.
Jun 2, 2021 11:25 AM ET
Alkermes Celebrates Mental Health Month
May is Mental Health Month! The COVID-19 pandemic has put mental health front and center. This month we encourage everyone to learn more, share resources, and consider how you can support those who are living with mental illness.
May 19, 2021 1:40 PM ET
Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month
DUBLIN, May 4, 2021 /3BL Media/ -- Alkermes plc (Nasdaq: ALKS) recently announced plans to present clinical data and outcomes research from its...
May 4, 2021 10:50 AM ET
Alkermes Supports Mental Health Clinical Research
Alongside the The STARR Coalition, we recognize the need to support mental health research. Scientific, evidence-based mental health research is essential. To learn more about our commitment to supporting mental health clinical research and how to take actionable steps, visit: https://bit.ly/3bSkreC 
Apr 26, 2021 1:50 PM ET
Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society
DUBLIN, April 22, 2021 /3BL Media/ -- Alkermes plc (Nasdaq: ALKS) recently announced the presentation of new research from its psychiatry...
Apr 22, 2021 9:35 AM ET

Pages